Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 7/20 | 0.41 |
| ▸ | RAB9A | P51151 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454362 | 0.79 | SMN1; SMN2 (0.45) | NPC1RAB9ASMN1; SMN2MAPK1SMPD1 | |
| SCHEMBL5453454 | 0.75 | SMN1; SMN2 (0.48) | HDAC6HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL5449570 | 0.74 | SMN1; SMN2 (0.57) | HDAC6NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5445146 | 0.72 | SMN1; SMN2 (0.57) | HDAC6HDAC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5446339 | 0.71 | SMN1; SMN2 (0.50) | HDAC6HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL5451039 | 0.71 | NPC1 (0.53) | HDAC6NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL21938816 | 0.70 | RAB9A (0.66) | NPC1RAB9ASMN1; SMN2MAPK1KDM4E | |
| SCHEMBL21939043 | 0.68 | THRB (0.56) | HDAC6HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL24429344 | 0.67 | HDAC6 (0.49) | HDAC6HDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL10180179 | 0.66 | TSHR (0.53) | RAB9ASMN1; SMN2MAPK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-02-22 | — | — | US | claimed |
| EP-1664000-A1 | ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS | Arpida A/S (DK) | 2006-06-07 | — | — | EP | claimed |
| WO-2005026133-A1 | ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS | ARPIDA A/S (DK) | 2005-03-24 | — | — | WO | claimed |
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-02-22 | — | — | US | disclosed |
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-02-22 | — | — | US | disclosed |
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-02-22 | — | — | US | disclosed |
| EP-1664000-A1 | ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS | Arpida A/S (DK) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026133-A1 | ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS | ARPIDA A/S (DK) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | PDF, MRPL21, PEPD | HDAC6 184/4885HDAC1 2298/4885HDAC3 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.